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Accepted 19 February 2013AbstractObjective: To compare the assumptions and estimands across three approaches to estimate the effect of erythropoietin-stimulating
agents (ESAs) on mortality.
Study Design and Setting: Using data from the Renal Management Information System, we conducted two analyses using a change to
bundled payment that, we hypothesized, mimicked random assignment to ESA (preepost, difference-in-difference, and instrumental vari-
able analyses). A third analysis was based on multiply imputing potential outcomes using propensity scores.
Results: There were 311,087 recipients of ESAs and 13,095 non-recipients. In the preepost comparison, we identified no clear relation-
ship between bundled payment (measured by calendar time) and the incidence of death within 6 months (risk difference 1.5%; 95% con-
fidence interval [CI] 7.0%, 4.0%). In the instrumental variable analysis, the risk of mortality was similar among ESA recipients (risk
difference 0.9%; 95% CI 2.1, 0.3). In the multiple imputation analysis, we observed a 4.2% (95% CI 3.4%, 4.9%) absolute reduction
in mortality risk with the use of ESAs, but closer to the null for patients with baseline hematocrit level O36%.
Conclusion: Methods emanating from different disciplines often rely on different assumptions but can be informative about a similar
causal contrast. The implications of these distinct approaches are discussed.  2013 Elsevier Inc. All rights reserved.
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The estimation of causal effects from nonexperimental
studies is a venture common to many empirical disciplines.
As a result, multiple procedures for estimation of causal ef-
fects have been developed [1e3], emanating from different
intellectual traditions and relying on different assumptions.
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http://dx.doi.org/10.1016/j.jclinepi.2013.02.014perspectives [4], including those from econometrics, statis-
tics, health services research, and epidemiology [5]. How-
ever, researchers may be unfamiliar with the appropriate
assumptions and estimands produced by a particular ana-
lytic technique.
For example, in cohort studies in which the treatment
groups are matched on propensity score, differences in out-
comes are typically interpretable as the effect of the treat-
ment on the treated [6]. However, an instrumental variable
analysis used in the same data set and with the same expo-
sure specification will, under certain assumptions, produce
an estimate of the local-average treatment effect (LATE),
local to just those patients whose treatment choice was
affected by the instrument (the ‘‘compliers’’) [7]. The dif-
ferent analyses also carry distinct assumptions that make
them suitable for different applications. In certain cir-
cumstances, evaluation of policies may provide some
S43D.D. Dore et al. / Journal of Clinical Epidemiology 66 (2013) S42eS50What is new?
 The recent emphasis on comparative effectiveness
research has promoted interdisciplinary sharing of
methods, including those from econometrics, sta-
tistics, health services research, and epidemiology.
 We present three analyses that could be used
to estimate different types of causal effects of
erythropoietin-stimulating agents (ESAs) on mortal-
ity, including a preepost, difference-in-difference
comparison of a bundled payment policy that reduced
prescribing of ESAs, an instrumental variable analy-
sis derived from the bundled payment policy, and an
analysis that involved imputation of counterfactual
outcomes within levels of the propensity score.
 The specific estimands differ, as do the required as-
sumptions for causal inference in each analysis.
 The three analyses have different strengths andweak-
nesses for certain applications.
 Researchers from different disciplines in compara-
tive effectiveness research should work together to
develop the most appropriate design and analysis
for the causal question of interest.
information about the effect of a treatment whose use is
influenced by the policy [8], resulting in comparability be-
tween the policy effect and the effect of a treatment af-
fected by the policy.
The purpose of this article was to present a case study in
which the authors compared three methods for estimating
the effect of a class of anemia treatments, erythropoietin-
stimulating agents (ESAs), on mortality among patients
with end-stage renal disease (ESRD). ESAs are recombi-
nant glycoprotein hormones that mimic endogenous eryth-
ropoietin and treat anemia associated with chronic kidney
disease [9]. The first two methods have an econometric leg-
acy and leverage a Medicare payment policy change that
reduced the use of ESAs for patients with high hematocrit
level. The third technique multiply imputes counterfactual
outcomes (mortality) within levels of the propensity score,
allowing a more specific person-level analysis [10].2. Methods
2.1. Policy context for econometric analyses
Until December 31, 2010, Medicare reimbursed hemodi-
alysis providers separately for each dose of ESAs adminis-
tered, so that each dose resulted in additional revenue and
profit for the provider. Effective January 1, 2011, Medicare
introduced an ‘‘expanded bundled’’ payment of a fixed sumfor hemodialysis treatments, including the administration of
ESAs, so that providers can no longer earn more revenue by
increasing their use of ESAs [11]. The Medicare program
simultaneously introduced financial penalties that reduced
payments to hemodialysis providers with low performance
on a composite measure of three quality indicators. Three-
quarters of this composite score was based on the propor-
tion of ESRD patients with hematocrit level between 30%
and 36%. More than 95% of providers adopted the new
payment model immediately [11].
These changes in payment occurred within the context of
findings that treating patients with ESAs to higher hemoglo-
bin targets is associated with an increased risk of adverse
effects, including death [12e15]. The Food and Drug Ad-
ministration (FDA) issued a black-box warning cautioning
providers to not to exceed hemoglobin levels of 12 g/dL with
ESA treatment [16], and recently, the FDA issued a new
guideline suggesting that ESAs be used only to reduce the
frequency of transfusions [17]. As a result, after Medicare
implemented bundled payment for ESRD services, the use
of ESAs at the encounter level among patients with
hematocrit levelO36% immediately declined by 7e14 per-
centage points (Swaminathan S, Mor V, Mehrotra R, Trivedi
AN. Effect of bundled dialysis payments on use of erythro-
poiesis stimulating agents. Submitted 2012).
We viewed Medicare’s payment policy change and the
resulting reduction in the use of ESAs as an opportunity
to identify the effect of ESA use on the rate of mortality
at the patient level. We hypothesized that a comparison of
patients initially exposed to ESAs before bundled payment
with those initially exposed after the change in payment
policy would mimic random assignment to ESA treatment
for patients with an initial hematocrit level of O36% and
form the basis for an instrumental variable analysis [7].2.2. Data source and study population
We obtained data from the Renal Management Informa-
tion System (REMIS) on all ESRD patients undergoing
hemodialysis between January 1, 2007, and December 31,
2011, through the Centers for Medicare and Medicaid
Services (http://www.cms.gov/Research-Statistics-Data-and-
Systems/Files-for-Order/IdentifiableDataFiles/RenalManage
mentInformationSystem.html). REMIS data include infor-
mation on specific hemodialysis encounters, including each
patient’s baseline hematocrit level (for patients beginning
dialysis), a binary variable indicating whether patients re-
ceived ESA (recorded one to three times quarterly), and de-
mographic and clinical data. We restricted the study
population to patients beginning hemodialysis.
The three analyses presented in this article used different
time frames. Because analyses 1 and 2 relied on the policy
change, it was necessary to narrow the window of study to
around the time of the policy change (the year before and
after). Analysis 3 had no such requirement and was able
to accommodate all of the data (from 2007 to 2011).
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Date of death was collected from provider report on the
CMS 2746 Death Notification Form and linkage to the
Medicare enrollment file, as listed in the REMIS data.
Additional covariates included age, sex, race, albumin
level at time of entry into ESRD, hematocrit level at time
of entry into ESRD, body mass index (BMI), time since en-
tering the ESRD program, and the presence or absence of
a range of comorbid conditions assessed at the time of entry
into the ESRD program. Because we performed these anal-
yses for expository purposes, patients with missing values
of BMI, age, sex, albumin, and initial hematocrit level were
excluded from the analyses, and the results are subject to
the assumption that these data were missing completely at
random [18].2.4. Analysis 1: Comparison of mortality preepost
bundling of payment for ESRD using a difference-in-
differences analysis
Because the introduction of bundled payments reduced
prescribing of ESA therapy mainly among patients with
a hematocrit level O36%, we estimated the risk of 180-
day mortality in this population in the post-bundling period
relative to the pre-bundling period. We also estimated the
differential temporal change in the use of ESAs across he-
matocrit levels (36% andO36%) and risk of mortality. If
bundled payment policy affected only the use of ESAs (i.e.,
there were no changes in the population covariates between
the two periods) and the effect of the policy on patients
with hematocrit level 36% is negligible, then this method
provides an estimate of the average effect of bundled pay-
ment on mortality, mediated by the use of ESAs for those
patients whose hematocrit level is O36% and who do not
receive ESA because of the new policy. That is, any in-
crease or reduction in mortality would be attributable to
the effect of bundled payment on the use of ESAs.
The analysis took the form:Morti5b0þ b1Ti þ b2Di þ b3TiDiþ xib4þ ui;where T 5 1 for patients who began hemodialysis in the
first quarter of 2011 (post-bundling) and T 5 0 for patients
who began hemodialysis during the first quarter of 2010
(pre-bundling), Morti 5 1 if patient who began hemodialy-
sis in period T died within 180 days of beginning hemodi-
alysis, Di is a dummy variable 5 1 if the patient’s initial
hematocrit level was O36%, x is a vector of patient char-
acteristics, and ui is an identically, independently, and nor-
mally distributed error term. The coefficient of interest, b3,
plotted in Fig. 2, panel B, is the difference in the differ-
ences in the risk of 180-day mortality before and after bun-
dling (first differences) between patients with hematocrit
level O36% vs. 36% (second difference).
Ideally, this analysis would have been restricted to treat-
ment facilities that opted into the bundled payment system(as 95% of facilities did), because only those facilities were
affected by the policy change. However, the data did not in-
clude an indicator of which facilities opted for bundled
payment.
2.5. Analysis 2: Instrumental variable analysis
In the second analysis, we identified recipients of ESAs
whose baseline hematocrit level was O36% and whose
first hemodialysis treatment occurred in the first half of
the year preceding or the 6 months following the change
in payment policy, creating a variable, Z, assumed to be
an instrument corresponding with the date of first ESA ex-
posure. We classified ESA exposure, T, as a binary, time-
fixed measure of exposure status upon entry into REMIS.
Specifically, each recipient was classified as exposed if he
or she received ESA during the first recorded hemodialy-
sis visit.
We then conducted a two-stage least-squares analysis in
which we regressed the ESA treatment variable on the time
block of first hemodialysis (the proposed instrument) and
patient covariates:Ti5b0þ b1ZiþXib2 þ e1i ;
where Ti is ESA exposure status for patient i, Zi is the
instrumental variable for patient i (time block of first hemo-
dialysis treatment), X represents measured patient covari-
ates, and e1i is a randomly distributed error term. In stage
2, we fit a model of the formYi5a0þ a1 bT iþXia2þ e2i ;
where Yi is mortality, bT i is the predicted value of ESA ex-
posure given the proposed instrumental variable from the
first model, a1 provides an estimate of the risk difference
of mortality corresponding with ESA use at baseline, and
e2i is a randomly distributed error term.
2.6. Analysis 3: Multiple imputation of potential
outcomes
In this analysis, we estimated the causal effect of treat-
ment with ESAs on 180-day mortality relative to nontreat-
ment using a broader set of data (2007e2011). This
analysis operationalized the Rubin Causal Modeling frame-
work [1], in which a causal effect of a binary treatment with
ESAs (W ) on mortality (Y ) for person i (i5 1,., N ) is de-
fined by a comparison of two ‘‘potential’’ outcomes,Yi(1) and
Yi(0), only one of which is observed for each patient (the un-
observed outcome is counterfactual and represents the expe-
rience of the same patient had he or she received the
alternative treatment). These potential outcomes are the out-
comes for each person under the two possible levels of expo-
sure W: Wi 5 1 indicates baseline exposure to ESA, and
Wi 5 0 indicates the control level (nonexposure), where
Yi(1) and Yi(0) would be realized under the active and control
treatment conditions, respectively.
Table 1. Distribution of baseline covariates for users and non-users of
erythropoietin-stimulating agents, Renal Management Information
System, 2007e2011
Covariate
Users
(n [ 311,087),
%
Non-users
(n [ 13,095),
%
Men 44.6 43.0
Age (years), mean 66.4 61.2
Race
Black 27.7 31.8
White 67.0 61.2
Other 5.3 7.0
Initial albumin level, g/dL
0e1 0.2 0.2
1e2 5.8 5.3
2e3 30.7 27.0
3e4 37.2 40.0
5e6 5.9 8.5
Initial hematocrit level, mean % 29.7 29.1
Year of first hemodialysis treatment
2007 23.7 7.7
2008 23.3 20.0
2009 22.3 23.1
2010 21.0 29.6
2011 9.7 19.6
Initial hemodialysis time O4 hours 1.0 1.4
Fistula or graft used at initial
hemodialysis
17.1 24.1
Fistula used at initial hemodialysis 13.7 20.6
Catheter used at initial hemodialysis 82.2 75.4
Diagnoses
Diabetes 46.5 43.4
Hypertension 30.2 31.0
Body mass index, mean 28.8 29.3
Obesity 36.7 39.7
Congestive heart failure 36.2 28.0
Ischemic heart disease 23.8 18.5
Myocardial infarction 19.6 15.6
Hypertension 13.6 13.7
Tobacco use 6.1 6.5
This table represents the study population and exposure definition
used in analysis 3.
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modialysis encounter (Wi 5 1) vs. never receiving ESA
(Wi 5 0) at any hemodialysis encounter after hemodialysis
initiation. Follow-up began at the initiation of hemodialy-
sis. Approximately 92% of ESA recipients received ESA
at the time of the first recorded hemodialysis treatment,
making this measure of exposure comparable to the base-
line measure used in analysis 2 and also making it unlikely
that bias resulted from the misclassification of unexposed
immortal time before treatment or selection bias [19e21].
Because only one potential outcome is observed for
each patient, we cannot directly estimate the causal effect
for person i. Instead, we must observe multiple people,
some exposed to ESAs (Wi 5 1) and others unexposed
(Wi 5 0) and consider their covariates, Xi, which we as-
sumed were unaffected by Wi. We accounted for the cova-
riates (Xi) using estimated propensity scores for each
person [22].
We implemented a novel methodology for imputing the
missing counterfactual outcomes and estimating the treat-
ment effect. First, we estimated the propensity scores using
an algorithm described by Imbens and Rubin [23]. Patients
for whom no person in the opposing exposure group had
a similar estimated propensity score were excluded [24].
Second, we partitioned the patients into 10 equal-size strata
based on their estimated propensity score. We then com-
pared the distributions of the covariates and all second-
order interactions of the covariates in the treatment and
control groups in each stratum. If the stratum-specific dis-
tributions of covariates and interactions in the treatment
and comparison groups differed, we went back to the first
step. We iterated between the first two steps until the distri-
butions of the covariates in the treatment and control
groups in each stratum were similar.
Third, we estimated the response surfaces (distribution
of Y(W)jX ) using two separate regression spline models.
The knots of the spline were placed at the boundaries of
strata from step 2. Fourth, we used the estimated response
surfaces from the third step to multiply impute the missing
potential outcome. For the patients in the comparison group
we imputed Yi(1) and for patients in the ESA group we im-
puted Yi(0).
Imputing the missing potential outcomes only once can-
not adequately account for the uncertainty of the response
surfaces or the uncertainty in the missing potential out-
comes [18,25]. Using multiple imputation with Rubin’s
[25] combining rule results in intervals that take into ac-
count the additional variability because of the missing po-
tential outcomes and unknown parameters and typically
provides approximately valid statistical procedures. Finally,
we estimated the average difference in 180-day mortality
among strata of the initial hematocrit level. Note that the
initial hematocrit value was included in the propensity
score model. Complete description and theoretical justifica-
tion for this procedure can be found in recent publications
[10,25,26].3. Results
3.1. Characteristics of recipients and non-recipients of
ESAs
There were 311,087 recipients of ESAs between
2007 and 2011 and 13,095 non-recipients (Table 1). With
respect to analyses 1 and 2, most, but not all, covariates
were balanced across the periods defined before and after
the adoption of the bundling payment policy (Table 2,
first stage). For example, the mean age and albumin
levels were appreciably higher in the post-bundling
period. There was a similar distribution of the esti-
mated propensity score across exposure categories within
deciles of the estimated propensity score after removal of
two ESA recipients (from 13,093) and 158 non-recipients
(from 310,929) for whom there was no person in the op-
posing exposure group with a similar propensity score
(Fig. 1).
Table 2. Estimated difference in risk of mortality comparing use of
ESAs to non-use using the bundled payment policy as an
instrumental variable, Renal Management Information System,
2010e2011
First stage: difference in prevalence of covariates and receipt of ESAs
Difference (Z 5 1)  (Z 5 0)a
ESA use, overall 1.5%***
Men 0.001
Age (years) 0.27*
Race
Black 0.005
White 0.002
Other 0.006
Initial albumin level, mean g/dL 0.012*
Initial hematocrit level, mean % 0.32*
Initial hemodialysis time O4 hours 0.02
Fistula used at initial hemodialysis 0.004
Catheter used at initial hemodialysis 0.003
Diagnoses
Diabetes 0.004
Hypertension 0.003
Body mass index, mean kg/m2 0.007
Congestive heart failure 0.002
Ischemic heart disease 0.001
Myocardial infarction 0.002
Tobacco use 0.003*
First-stage F-statistic on instrumental
variable
12.62
Second stage: estimate of ESA effect Adjustedb 180-day
risk difference
of death (95% CI)
Receipt of ESAs 0.9 (2.1, 0.3)
Abbreviations: ESAs, erythropoietin-stimulating agents; CI, confi-
dence interval.
*Significant at 10% level, ***Significant at 1% level.
a Z 5 1 if patient began hemodialysis between January 1, 2011,
and June 30, 2011, and Z 5 0 if patient began hemodialysis between
January 1, 2010, and June 30, 2010.
b Estimated coefficient from two-stage least-squares regression
model after adjusting for covariates shown in the first stage.
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Fig. 2, panel A, shows a comparison of the 180-day mor-
tality risk among patients whose first hemodialysis treat-
ment was before or after the adoption of the bundled
payment policy, by first hematocrit level. Because current
treatment guidelines and treatment quality incentive param-
eters [27] suggest that the dose of ESAs should be reduced
if the patient’s hematocrit level exceeds 36%, we would ex-
pect that any effect of bundled payment on mortality would
be stronger at higher levels of hematocrit. In these data, we
see no clear relationship between bundled payment (mea-
sured by calendar time) and the incidence of death. The in-
creased variability in the rate of death at higher hematocrit
levels is ascribable to a smaller sample size. The mean he-
matocrit level at first hemodialysis treatment was approxi-
mately 29%. The results also show no differences in the
rate of mortality before and after the adoption of bundled
payment among patients with hematocrit level O36%
(Fig. 2, panel B).3.3. Analysis 2: Instrumental variable analysis
Overall, patients who began hemodialysis in the first
half of 2011 were approximately 1.5% less likely to re-
ceive ESAs than their counterparts who began hemodialy-
sis in the first half of 2010 (Table 2), suggesting that time
relative to implementation of bundled payment is a weak
potential instrument [28]. Although the summary statistics
in Table 2 suggest that the proposed instrument is not
highly correlated with many of the covariates used in
the model, there still exists a correlation with age, initial
albumin level, and initial hematocrit level. This informa-
tion suggests the possibility of some correlation between
the instrumental variable and important unmeasured cova-
riates. Under the assumption that we have a valid instru-
mental variable, the risk difference of 180-day mortality
associated with the receipt of ESAs was 0.9 (95% con-
fidence interval [CI] 2.1, 0.3), but the interval estimate
is consistent with no difference in the risk of mortality.
The point estimate is interpretable as a nonsignificant pro-
tective effect of ESAs.
3.4. Analysis 3: Multiple imputation of potential
outcomes
After multiple imputation of counterfactual outcomes
for recipients and non-recipients, we observed reductions
of approximately 3e5% in the risk of mortality among re-
cipients of ESAs across nearly all baseline levels of hemat-
ocrit (Fig. 3). The average decrease in absolute risk
comparing ESA use with non-use across levels of hemato-
crit was 4.2% (95% CI 3.4%, 4.9%). There was no clear ef-
fect of ESAs on mortality at hematocrit levels of 40% and
above, but the CIs in these strata were wide.4. Discussion
We present three analyses that could be used to estimate
different types of causal effects. The results from each ap-
proach are somewhat different, although qualitatively sim-
ilar in showing little or no effect of ESAs on the risk of
mortality for patients with higher levels of hematocrit.
The specific estimands differ, as do the required assump-
tions for causal inference in each case. Below we discuss
each of the assumptions and interpretation of each analysis
in reverse order.
4.1. Analysis 3
Analysis 3 is likely most familiar to investigators in
comparative effectiveness research. The values from this
analysis are interpretable as estimates of the effect of initial
treatment with ESAs among the full population of patients
receiving hemodialysis and in this case are comparable to
the effect among the treated (96% of patients received
treatment).
R, Ratio of variances of the propensity score in the ESA group relative to the comparison group 
B, Difference in the mean propensity score in the ESA group relative to the comparison group 
Fig. 1. Distribution of propensity score in each decile, Renal Management Information System, 20072011. ESA, erythropoietin-stimulating agent.
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many nonexperimental methods in comparative effective-
ness research, most importantly the assumption of no un-
measured confounding. The other assumptions required
for the estimates from analysis 3 to reflect a causal effect
are Rubin’s stable unit treatment value assumption (SUT-
VA) and that each patient has a positive probability of re-
ceiving ESAs [29].4.2. Analysis 2
In Analysis 2, the estimand produced is unclear. With in-
strumental variable analysis, estimating average treatment
effects for the population under study requires sometimes
untenable assumptions that affect the estimand produced
[30,31]. Indeed, the correlation between the proposed in-
strument and observed covariates suggests that our use of
‘‘time’’ as an instrumental variable is flawed to an unknown
degree and highlights the fundamental problem of instru-
mental variable analysis: finding a valid instrument. More-
over, in the presence of a heterogeneous treatment effect
(i.e., the treatment effect is not equal for each subject), in-
terpreting the treatment effect as an average effect (e.g.,
among the treated) is unwarranted.A commonly used assumption for the estimation of
causal effects from instrumental variables in the presence
of heterogeneity is monotonicity [7,31]. In analysis 2, the
presence of the bundled payment policy was treated as an
instrumental variable, taking the value of 1 if a patient en-
tered hemodialysis in the 6 months following the introduc-
tion of bundled payments and 0 if the patient entered
hemodialysis in the same months during the previous year.
In this case, monotonicity states that the probability of use
of ESAs among patients with baseline hematocrit level
O36% must be uniformly lower after bundled payment rel-
ative to that before bundled payment. Under this assump-
tion, the analysis identifies the causal effect of treatment
with ESAs on the risk of mortality among patients whose
exposure to ESAs was influenced by the bundled payment
policydthe compliers with bundled payment [7]. Whether
this method identifies a causal effect under the formality of
the Rubin causal model requires additional assumptions
about changes in care over the time before and after bun-
dled payment.
The comparability of this treatment effect with the av-
erage treatment effect estimated in analysis 3 (ie, among
the treated) is not immediately clear. Neither is it imme-
diately clear what subset of the study population makes
Fig. 2. Crude and adjusted cumulative incidence of 180-day mortality following first hemodialysis treatment by date of first dialysis treatment
(proxy for exposure to erythropoietin-stimulating agents), Renal Management Information System, 2008e2011. (A) Crude cumulative incidence
of 180-day mortality (2010e2011). (B) Adjusted estimates of difference in 180-day mortality before and after adoption of bundled payment for
ESRD services comparing baseline hematocrit level O36% vs. 36%.
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that involve identification of the compliers to whom the
estimated LATE applies), making it difficult to know
how applicable the estimate is to the target population
[32].
With analysis 2, the instrumental variable approach
aims to identify the causal effect without the assumption
of no unmeasured confounding but relies on other strong
assumptions including SUTVA. In addition to the as-
sumptions regarding treatment effect heterogeneity, for
a causal interpretation of analysis 2, we must assume that
(1) the instrumental variable (bundled payment) has
a causal effect on the use of ESAs (or is a surrogate
for such an instrument), (2) bundled payment affects mor-
tality only through its effect on the use of ESAs, and (3)
the effect of bundled payment on mortality is not associ-
ated with unmeasured patient characteristics [7,30,33].
Violations of these assumptions can result in bias. Forinstance, assumption (2) would be violated if the bundled
payment policy increased the use of iron or blood trans-
fusions, and these interventions affected mortality [33].
The magnitude of this bias can be large with even small
violations of assumption (2) if the instrumental variable
has a weak association with the exposure (as in the case
here) [34].
Analysis 2 also assumes that there is no treatment effect
heterogeneity by hematocrit level. If there is heterogeneity,
then the interpretability of the estimand is again compli-
cated because it applies only to the compliers. Moreover,
because there is only a weak correlation between bundled
payment and person-level use of ESAs, bundled payment
is a weak proxy for exposure to ESAs. Thus, in this analy-
sis, actual exposure to ESAs is misclassified and produces
an estimate of the effect of bundled payment on mortality
(Swaminathan et al., 2012) instead of the explicit effect
of ESA receipt on mortality.
Erythropoietin-Stimulating Agents Better  Non-use Better 
Fig. 3. Differences in the cumulative incidence of mortality compar-
ing users of erythropoietin-stimulating agents with non-users by the
initial hematocrit level, Renal Management Information System,
2007e2011.
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In analysis 1, we estimated changes in mortality after
transitioning from fee-for-service payment for ESAs ad-
ministered during hemodialysis to a fixed-sum, bundled he-
modialysis payment that includes the use of ESAsdthat is,
analysis 1 involved estimating the policy effect (Swamina-
than et al., 2012).
For an interpretation that analysis 1 estimates the causal
effect of ESA receipt (rather than the policy), assumptions
(2) and (3) from analysis 2 are required plus the assumption
that the bundled payment policy strongly affects the use of
ESAs among patients whose hematocrit level is O36 but
not at all among patients whose hematocrit level is 36%.
4.4. Comparing the approaches
These three analyses require different assumptions and
therefore have different strengths and weaknesses for certain
applications. To be sure, it is best to start with a carefully de-
signed causal question [35]. However, in the reality of public
health, clinical and policy decision makers often need infor-
mation on treatment effectiveness well before the ideal study
can be implemented, arguing for the availability of a range of
methods that could be applied to the available data.
It is important to note that comparability of these
methods is hard to evaluate when there is appreciable effect
heterogeneity. In the presence of effect heterogeneity, the
estimates from the three analyses could be startlingly dif-
ferent, because they apply to different subsets of the popu-
lation, even if they are unbiased [36].
Notably, however, the results of the three analyses for
patients with an initial hematocrit level of O36% are notdissimilar, and although all three findings rely on untested
assumptions, their qualitative similarity (despite their dif-
ferent analytic assumptions) provides information about
the robustness of the findings that would be missing if only
a single analysis had been performed.
More general limitations of these analyses deserve men-
tion. First, misclassification of exposure, outcome, and
covariates are possible in the REMIS data. Of particular
importance is exposure misclassification, because our
time-fixed, binary measures of ESA use do not capture
the complex time-dependent nature of ESA use in common
practice [37]. This point is particularly salient for readers
who are interested in the clinical implications of our work.
We did not intend for our analyses to directly inform clin-
ical practice. Instead, we used this topic as an example for
comparing different methodological approaches. ESAs are
used in a more nuanced way than this article captures. They
are not prescribed in a binary waydtreat always or never
treatdbut instead their use involves careful tracking of
treatment response and regular dosage adjustments. This
article does not address these issues.
Second, because the data are left censored, it is difficult to
characterize patients as new or prevalent users of ESAs or to
identify the true baseline value of hematocrit. Third, none of
the analyses presented accounted for time-dependent con-
founding. Indeed, all the analyses make the assumption that
the steps taken to address confoundingdthat is, covariate
measurement and propensity scoring in analysis 3 and the in-
strumental variable in analyses 1 and 2dare sufficient. Our
exposure measures are time fixed, and similarly, we do not
explicitly address time-dependent confounding. Fourth, be-
cause the rate of mortality is high in patients beginning dial-
ysis, loss to follow-up remains a concern. Fifth, we did not
exclude patients with polycystic kidney disease (PKD),
who typically do not need ESAs, and whose inclusion may
weaken the instrumental variables. Patients with PKDwould
be expected to account for 10% of the study population
[38]. Each of these assumptions has been discussed in the lit-
erature on pharmacoepidemiology and comparative effec-
tiveness research [39,40].
Additionally, the proposed instrumental variable was
weakly correlated with person-level use of ESAs, whereas
it is more strongly associated with encounter-level use of
ESAs (Swaminathan et al., 2012). Thus, it appears that phy-
sicians have reduced the intensity of within-patient ESA
use but have not reduced the number of patients who re-
ceive ESA.
In summary, applied researchers from different back-
grounds bring different approaches to inferring the causal
effect of a treatment in nonexperimental studies. Although
not always feasible, each study should have clear aims
based not on the analytical procedure that the researcher in-
tends to use but rather on the scientific question at hand.
Once the aims of the research are clearly defined, an appro-
priate method should be chosen with care and only after
checking whether the assumptions made by this method
S50 D.D. Dore et al. / Journal of Clinical Epidemiology 66 (2013) S42eS50can be defended by the available data. It is true that some
of the assumptions made are unverifiable, but researchers
should attempt to examine whether the data available refute
the analytic assumptions and apply substantive expertise
and sensitivity analyses to evaluate whether the assump-
tions for causal inference in a given application are
defensible.Acknowledgments
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